Orion Portfolio Solutions LLC Reduces Stock Position in Qiagen (NYSE:QGEN)

Orion Portfolio Solutions LLC lessened its holdings in Qiagen (NYSE:QGEN) by 17.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,621 shares of the company’s stock after selling 2,399 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Qiagen were worth $530,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. XTX Topco Ltd boosted its stake in Qiagen by 129.3% in the third quarter. XTX Topco Ltd now owns 20,192 shares of the company’s stock valued at $920,000 after acquiring an additional 11,385 shares in the last quarter. Zurich Insurance Group Ltd FI boosted its stake in Qiagen by 5.7% in the third quarter. Zurich Insurance Group Ltd FI now owns 5,291 shares of the company’s stock valued at $239,000 after acquiring an additional 287 shares in the last quarter. National Bank of Canada FI boosted its stake in Qiagen by 1.2% in the third quarter. National Bank of Canada FI now owns 25,636 shares of the company’s stock valued at $1,155,000 after acquiring an additional 308 shares in the last quarter. Wellington Management Group LLP boosted its stake in Qiagen by 77.7% in the third quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock valued at $963,386,000 after acquiring an additional 9,293,040 shares in the last quarter. Finally, State Street Corp boosted its stake in Qiagen by 3.9% in the third quarter. State Street Corp now owns 2,380,008 shares of the company’s stock valued at $108,457,000 after acquiring an additional 90,181 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on QGEN. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research note on Thursday, October 17th. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a research note on Thursday, October 17th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $54.00 target price (up previously from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $51.15.

Qiagen Stock Down 0.1 %

QGEN stock opened at $45.34 on Wednesday. The stock has a market capitalization of $10.35 billion, a P/E ratio of 116.26, a PEG ratio of 3.52 and a beta of 0.35. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. Qiagen has a one year low of $39.03 and a one year high of $47.44. The company has a 50 day moving average price of $43.25 and a two-hundred day moving average price of $43.74.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.